Seer, Inc. (SEER)
Market Cap | 671.41M |
Revenue (ttm) | 656,000 |
Net Income (ttm) | -32.78M |
Shares Out | 13.22M |
EPS (ttm) | -2.48 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | April 23 |
Last Price | $50.80 |
Previous Close | $50.73 |
Change ($) | 0.07 |
Change (%) | 0.14% |
Day's Open | 51.05 |
Day's Range | 50.40 - 51.95 |
Day's Volume | 43,146 |
52-Week Range | 38.37 - 86.55 |
REDWOOD CITY, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report fina...
Seer Proteographâ„¢ Product Suite combined with SCIEX mass spectrometry technology to provide unbiased, deep proteomics workflows for labs of all types Seer Proteographâ„¢ Product Suite combined with SCIEX ...
Added Salk Institute as collaboration customer and SCIEX as new commercial partner Added Salk Institute as collaboration customer and SCIEX as new commercial partner
REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report fina...
Lee Ainslie (Trades, Portfolio), the founder and CEO of Maverick Capital, recently disclosed the firm's portfolio changes for the fourth quarter of 2020, which ended on Dec. 31.
REDWOOD CITY, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participa...
REDWOOD CITY, Calif. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the closing of an underwritten publ...
REDWOOD CITY, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the pricing of an underwritten publi...
REDWOOD CITY, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the commencement of a proposed under...
Combination of Thermo Fisher's market leading Orbitrap mass spectrometer portfolio with Seer Proteographâ„¢ Product Suite to expand availability of end-to-end proteomics in new markets Combination of Ther...
REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid ...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...
REDWOOD CITY, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable pr...
The hot category of initial public offerings in the biotechnology sector continues, with two set to trade Friday: Seer and Silverback Therapeutics. Both priced above their estimated range.
REDWOOD CITY, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable pr...
About SEER
Seer, Inc. aims to enable exceptional scientific outcomes by commercializing transformative products for researchers to unlock deep, unbiased biological information. Our initial product, the Proteograph Product Suite (Proteograph), will leverage our proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome. Our Proteograph Product Suite is an integrated solution that is comprised of consumables, an automation instrument and software. Our Proteograph provides an easy-to-use wo... [Read more...]
Industry Biotechnology | IPO Date Dec 4, 2020 |
CEO Omid Farokhzad | Employees 60 |
Stock Exchange NASDAQ | Ticker Symbol SEER |
Financial Performance
In 2020, Seer, Inc's revenue was $656,000, an increase of 465.52% compared to the previous year's $116,000. Losses were -$32.78 million, 104.4% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for Seer, Inc stock is "Buy." The 12-month stock price forecast is 63.67, which is an increase of 25.33% from the latest price.